The Epstein-Barr virus (EBV) proteins EBNA1, EBNA2, EBNA3A, EBNA3C, LMP1 and EBNA-LP are essential for the in vitro immortalization of primary B lymphocytes by EBV. EBNA2 is a transcriptional activator of viral and cellular genes. Both EBNA3A and EBNA3C have been shown to specifically inhibit EBNA2-activated transcription by direct interaction with RBP-Jκ, a cellular DNA-binding factor known to recruit EBNA2 to EBNA2-responsive genes. This interaction interferes with the binding of RBP-Jκ to DNA in vitro, and this is probably the mechanism by which EBNA3A and EBNA3C repress EBNA2-activated transcription in vivo. EBNA3A and EBNA3C
Introduction
Epstein-Barr Virus (EBV) is a human herpesvirus which is the causal agent for infectious mononucleosis. EBV is also associated with several malignancies including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease and B and T lymphomas in immunodepressed individuals. A striking property of the virus is its ability to immortalize Blymphocytes in vitro. In such immortalized cells, the viral genome persists and a limited set of viral genes is expressed, defining a type III latency. The products of these genes include six nuclear proteins (EBNA1, 2, 3A, 3B, 3C and EBNA-LP), three membrane proteins (LMP1, TP1 and TP2) and two small nuclear RNAs (EBER1 and EBER2) (for a review see Kieff, 1996) . Of these gene products, the EBV nuclear proteins EBNA2, EBNA-LP, EBNA3A, EBNA3C and the EBV integral membrane protein LMP1 are essential for the EBV-induced proliferation of B cells (Cohen et al., 1989 ; Kaye et al., 1993 ; Mannick et al., 1991 ; Tomkinson et al., 1993) .
EBNA2 has been shown to be necessary for both the initiation (Sinclair et al., 1994) and maintenance of immortalAuthor for correspondence : Evelyne Manet.
Fax j33 4 72 72 86 86. e-mail emanet!cri.ens-lyon.fr also directly repress transcription when tethered to a promoter via the DNA-binding domain of the yeast Gal4 protein. As RBP-Jκ has been previously shown to be a repressor in mammalian cells, this repression could be due to the recruitment of RBP-Jκ by Gal4-EBNA3A and 3C. In this study, we have precisely mapped the domain of EBNA3A involved in the interaction with RBP-Jκ and we have shown that interaction with RBP-Jκ is not required for the Gal4-EBNA3A-mediated repression. Furthermore, we have characterized in EBNA3A a domain of 143 amino acids which is necessary and sufficient for EBNA3A-dependent repression.
ization (Kempkes et al., 1995) . It is a transcription factor that up-regulates the expression of the cellular genes CD21, CD23 and c-fgr (Calender et al., 1987 ; Cordier et al., 1990 ; Knuston, 1990 ; and EBV genes EBNA1, EBNA2, EBNA-LP, EBNA3A, EBNA3B, EBNA3C, LMP1, TP1 and TP2 (Abbot et al., 1990 ; Fahraeus et al., 1990 ; Rooney et al., 1992 ; Sung et al., 1991 ; Woisetchlaeger et al., 1990 ; Zimber-Strobl et al., 1991) . EBNA2 does not bind directly to DNA but appears to be targeted to its responsive promoters through direct interaction with the cellular specific DNA-binding protein RBP-Jκ Henkel et al., 1994 ; Ling et al., 1993 ; Waltzer et al., 1994 ; Zimber-Strobl et al., 1994) . The interaction between EBNA2 and RBP-Jκ is essential for the immortalization of primary B lymphocytes .
More recently, it has been shown that RBP-Jκ is also a direct target for the EBNA3A, 3B and 3C proteins (Krauer et al., 1996 ; Robertson et al., 1995 Robertson et al., , 1996 Waltzer et al., 1996 ; Zhao et al., 1996) . EBNA3A, -3B and -3C mRNAs are transcribed from three tandemly arranged genes in the EBV genome. The three EBNA3 proteins have related structures as well as a relatively well-conserved N-terminal domain (up to 28 % amino acid identity). However, these proteins probably have unique functions since recombinant EBVs that carry null mutations in either EBNA3A or EBNA3C are non-immortalizing (Tomkinson et al., 1993) . A number of cellular and viral genes have been reported to be up-or downregulated by one or the other of the EBNA3s although it is not clear if this is a direct effect : EBNA3C up-regulates the expression of CD21 in non-EBV-infected Burkitt's lymphoma (BL) cells and LMP-1 in G1-arrested EBVinfected Raji cells (Allday & Farrell, 1994) . EBNA3B upregulates the cytoskeletal protein vimentin as well as the activation antigen CD40 and down-regulates the Burkitt's lymphoma-associated antigen BLA\CD77 when stably expressed in the EBV-negative BL cell line DG75 (Silins & Sculley, 1994) . Stable co-expression of the three EBNA3 proteins in DG75 cells also upregulates pleckstrin (Kienzle et al., 1996) .
The most documented and common function of the EBNA3 proteins is their capacity to inhibit EBNA2-mediated activation of the TP1 and LMP1 promoters in transient expression assays (Le Roux et al., 1994 ; Marshall & Sample, 1995 ; Robertson et al., 1995) . It is now accepted that this inhibition is probably due to a direct interaction between EBNA3A, 3B or 3C and RBP-Jκ, resulting in the inhibition of binding of RBP-Jκ to DNA both in vitro and in vivo (Robertson et al., 1995 ; Waltzer et al., 1996) . Recently, it has also been shown that both EBNA3A and EBNA3C can act as repressors when tethered to DNA via the DNA-binding domain of the yeast transcription factor Gal4 Waltzer et al., 1996) . Since RBP-Jκ has been shown to be a repressor in mammalian cells (Dou et al., 1994 ; Hsieh & Hayward, 1995 ; Waltzer et al., 1995) , it is therefore possible that Gal4-EBNA3A-or 3C-mediated repression is due to the recruitment of RBP-Jκ onto the DNA by these fusion proteins.
In the present study, we have precisely mapped the EBNA3A domain mediating the interaction with RBP-Jκ. Surprisingly, when the interaction between EBNA3A and RBP-Jκ was impaired by specific mutagenesis in EBNA3A, the EBNA3A mutant still acted as a repressor when fused to the Gal4 DNA-binding domain. We then precisely mapped the EBNA3A domain responsible for RBP-Jκ-independent repression. Specific deletion of this domain completely impaired Gal4-EBNA3A repressor activity although RBP-Jκ was still recruited by the mutated fusion protein.
Methods
Plasmids. Reporter plasmids pG4-TK-CAT and pTK-CAT-Cp4x, and expression vectors for EBNA3A and RBP-VP16 (pSG5Flag-EBNA3A and pSG5flagRBP-VP16) have been described previously (Waltzer et al., 1995) . Plasmid pGal4-EBNA3A that contains full-length EBNA3A fused to the Gal4 DNA-binding domain was generated in two steps. Firstly, a XhoI restriction site was inserted upstream of the initiation codon of EBNA3A in plasmid pSG5-EBNA3A by site-directed mutagenesis (Clontech Transformer kit) using the oligonucleotide 5h GGTATCGGGCTCGAGACAAAATGG 3h to generate pSG5-EBNA3A-Xhoj. Secondly, a XhoI-XhoI fragment from pSG5-EBNA3A-Xhoj, containing the EBNA3A ORF, was cloned into the XhoI site of plasmid pG4MpolyII (Webster et al., 1989) .
Expression plasmids for Gal4-EBNA3A deletion mutants were generated in the following way : pGal4-EBNA3A(1-234) was generated by inserting a XhoI-SacI fragment from pSG5Flag-EBNA3A between the XhoI and SacI sites of pG4MpolyII ; pGal4-EBNA3A(234-575) by inserting a SacI (blunted)-BssHII(blunted) fragment from pSG5Flag-EBNA3A into the KpnI site (blunted) of pG4MpolyII ; pGal4-EBNA3A(575-944) by inserting a BssHII(blunted)-BglII fragment from pSG5Flag-EBNA3A between the BamHI(blunted) and BglII sites of pG4MpolyII ; pGal4-EBNA3A(125-944) by inserting a BamHI fragment from pSG5-EBNA3A plasmid into the BamHI site of pG4MpolyII ; pGal4-EBNA3A(125-575) by inserting a BamHI-BssHII(blunted) fragment from pGal4-EBNA3A(125-944) between the BamHI and SacI(blunted) sites of pG4MpolyII ; pGal4-EBNA3A(1-138) mutant by inserting a XhoI-NcoI(blunted) fragment from pGal4-EBNA3A between the XhoI and BamHI(blunted) sites of pG4MpolyII ; pGal4-EBNA3A(1-172) by removing a BstEII-SacI fragment from pGal4-EBNA3A(1-234) and religating the plasmid after blunting of the extremities ; pGal4-EBNA3A(172-234) by inserting a BstEII(blunted)-SacI fragment from pGal4-EBNA3A(1-234) between the KpnI (blunted) and SacI sites of pG4MpolyII ; pGal4-EBNA3A(172-575) by inserting a BstEII-BssHII blunted fragment from pGal4-EBNA3A into the KpnI(blunted) site of pG4MpolyII ; Gal4-EBNA3A(138-234) mutant by inserting a NcoI(blunted)-SacI fragment from pGal4-EBNA3A(1-234) between the BamHI(blunted) and SacI sites of pG4MpolyII ; pGal4-EBNA3A(125-234) by inserting a BamHI(blunted)-SacI fragment from pGal4-EBNA3A(1-234) between the KpnI(blunted) and SacI sites of pG4MpolyII ; pGal4-EBNA3A(234-944) by inserting a SpeI-XbaI fragment from pGal4-EBNA3A between the SpeI and XbaI sites of pGal4-EBNA3A(234-575) ; pGal4-EBNA3A∆125-138 by inserting a NcoI(blunted)-SpeI fragment from pGal4-EBNA3A between the BamHI (blunted) and SpeI sites of pGal4-EBNA3A ; and pGal4-EBNA3A(524-666) by inserting a StuI-ScaI fragment from pSG5-Flag-EBNA3A plasmid into the KpnI(blunted) site of pG4MpolyII.
Transfections. The plasmids used for transfection were prepared by the alkaline lysis method and purified through two CsCl gradients. The DNAs were in the same topological state as assayed by agarose gel electrophoresis. HeLa cells were grown at 37 mC in DMEM (Gibco) supplemented with 10 % foetal calf serum and were seeded at 5i10& cells per 100 mm Petri dish 8 h prior to transfection. Transfections were performed by the calcium phosphate precipitation method. Cells were mixed with the appropriate DNAs : typically 15 µg of DNA was used which included the expression vectors and plasmids carrying the reporter genes. The amount of SV40 promoter transfected was kept constant by the addition of pSG5 to the transfection reaction when necessary. Transfected cells were washed and collected 48 h after transfection.
The EBV-negative human Burkitt's lymphoma-derived cell line DG75 was grown at 37 mC in RPMI 1640 medium, supplemented with 10 % foetal calf serum. For transfections, approximately 5i10' cells in the exponential phase of growth were pelleted and resuspended in 250 µl of RPMI 1640 medium. The cell suspension was transferred into a chilled cuvette containing the relevant DNA and electroporated using a Bio-Rad gene pulser (220 V, 960 µF). The transfected cells were then resuspended in 10 ml of RPMI 1640 and incubated for 48 h. Each series of transfections was repeated several times.
Immunodetection. Cells were washed with cold PBS and incubated with 100 µl of RIPA buffer. Equal amounts of protein were loaded and separated on PAGE, and transferred to a nitrocellulose membrane (Schleicher & Schuell) by electroblotting. The membranes were first incubated with a mouse anti-Gal4 monoclonal antibody (RK5C1 from CAT-ELISA. This was done with the Boehringer Mannheim CAT-ELISA kit following the manufacturer's instructions. After transfection, cells were lysed in 1 ml of lysis buffer and the amount of CAT protein produced was calculated for the total amount of protein extracted.
Results

Mapping of the EBNA3A domain mediating the interaction with RBP-Jκ
A way to evaluate the hypothesis that Gal4-EBNA3A represses transcription by recruiting the cellular repressor RBP-Jκ, would be to examine the effect on Gal4-EBNA3A-mediated repression of a specific mutation in Gal4-EBNA3A that impairs its interaction with RBP-Jκ. In order to achieve this, we first mapped the domain of EBNA3A mediating the interaction with RBP-Jκ by using a two-hybrid type assay in mammalian cells. For this assay we used a fusion protein made between EBNA3A and the yeast protein Gal4 DNA-binding domain (Gal4-EBNA3A, Fig. 1 a) , a fusion protein between RBP-Jκ and the herpes simplex virus VP16 activation domain (RBP-VP16, Fig. 1 a) and the pG4-TK-CAT reporter plasmid in which transcription of the CAT gene is under the control of the TK promoter and six Gal4 binding sites (Fig. 1 a) . In agreement with our previously published results (Waltzer et al., 1996) , the transfection of HeLa cells with pG4-TK-CAT resulted in basal expression of CAT from the reporter plasmid ( Fig. 1 b, lane1) . Co-transfection with an expression vector for Gal4-EBNA3A resulted in a decrease in the amount of CAT protein expressed from the reporter plasmid pG4-TK-CAT ( Fig. 1 b, compare lanes 3 and 4 to lane 1). This repression was not induced by expression of the Gal4 DNA-binding domain alone (Fig. 1 b, lane 2) and correlates with the specific recruitment of Gal4-EBNA3A onto the DNA, as expression of EBNA3A (not fused to the Gal4 DNA-binding domain) did not affect the level of CAT expression (Fig. 1 b, lane 8) . However, when expression vectors for Gal4-EBNA3A and RBP-VP16 were co-transfected together with pG4-TK-CAT, the amount of CAT protein expressed increased (Fig. 1 b, lanes 5 and 6) . As no effect of RBP-VP16 was detected in the absence of Gal4-EBNA3A (Fig. 1 b, lane 7) this activation of CAT expression can be considered to be the result of the recruitment of RBP-VP16 onto the DNA by Gal4-EBNA3A and is thus a convenient assay for interactions between EBNA3A and RBP-Jκ in vivo.
We thus constructed a series of vectors containing overlapping fragments of EBNA3A fused to the Gal4 DNAbinding domain (Fig. 2 a) to investigate which of the EBNA3A fragments recruit RBP-VP16. Expression plasmids for these fusion proteins were co-transfected into HeLa cells, together with the expression vector for RBP-VP16 and the reporter construct pG4-TK-CAT. The amounts of the various proteins expressed were evaluated by Western blot analysis using an antibody which recognized the Gal4 moiety of the fusion proteins. All Gal4-EBNA3A mutants were produced in quantities comparable to Gal4-EBNA3A (data not shown). As shown in Fig. 2 (b) , only four Gal4-fusion proteins were able to recruit RBP-VP16 : the wild-type Gal4-EBNA3A protein (Fig.  2 b, lane 3) and the fusion proteins Gal4-EBNA3A(1-234), Gal4-EBNA3A(125-944), Gal4-EBNA3A(125-575) or Gal4-EBNA3A(125-234) (Fig. 2 b, lanes 4, 7, 8 and 14 respectively). Thus, the smallest EBNA3A fragment interacting with RBP-VP16 lies between amino acids 125 and 234. Interestingly, neither Gal4-EBNA3A(172-234) nor Gal4-EBNA3A(138-234) was able to recruit RBP-VP16 (Fig. 2 b , lanes 11 and 13 respectively) which suggests that the 13 amino acids between residues 125 and 138 at the N terminus of the DGF P.-Y. Bourillot and others P.-Y. Bourillot and others domain delimited above are crucial for the interaction with RBP-VP16 and thereby for the interaction with RBP-Jκ.
Gal4-EBNA3A repression of transcription is not mediated by interaction with RBP-Jκ
Having mapped the EBNA3A domain mediating the interaction with RBP-Jκ to amino acids 125-138, we then tested whether a Gal4-EBNA3A protein in which these amino acids were deleted (mutant Gal4-EBNA3A∆125-138) could still repress transcription and recruit RBP-VP16, as compared to GAL4-EBNA3A(1-944) and Gal4-EBNA3A(125-234) (Fig. 3 a) . Expression plasmids for each protein were cotransfected with the reporter construct pG4-TK-CAT, either alone or together with an expression plasmid for RBP-VP16, in the EBV-negative human lymphoid cell line DG75. All the Gal4 fusion proteins were expressed at comparable levels as shown by immunoblot analysis (Fig. 3 c) . As expected, the full-length EBNA3A fused to the Gal4 DNA-binding domain was able to recruit RBP-VP16 (Fig. 3 b, lane 3) and act as a repressor in the absence of RBP-VP16 (Fig. 3 b, lane 4) , demonstrating that both recruitment of RBP-Jκ and repression of transcription by Gal4-EBNA3A occurred in B-cells as well as in HeLa cells. Protein , which contains the minimum domain of EBNA3A that is able to recruit RBP-VP16 (Fig. 3 b, lane 5) , was no longer a repressor (Fig. 3 b, lane 6) . Interestingly Gal4-EBNA3A∆125-138, which did not recruit RBP-VP16 (Fig. 3 b, lanes 7) , was still a repressor (Fig. 3 b, lanes  8) . Thus, although deletion of amino acids 125-138 of EBNA3A completely abolished the interaction with RBP-VP16, this mutant expressed alone was still able to repress expression from the reporter construct with the same efficiency as Gal4-EBNA3A. These results strongly suggest that the repression of transcription and the ability of EBNA3A to interact with RBP-Jκ are not directly correlated.
In order to confirm that the Gal4-EBNA3A∆125-138 protein did not interact with RBP-Jκ, we also performed the following experiment. We used a reporter construct containing four RBP-Jκ binding sites cloned upstream of the TK promoter and the CAT gene (plasmid pTK-CAT-Cp4x ; Fig. 4 a) . The RBP-VP16 fusion protein binds and activates transcription from this artificial promoter (Fig. 4 b, compare lanes 2 and 3 to lane 1) (Waltzer et al., 1995) . When EBNA3A was co-expressed in the transfections, activation of transcription by RBP-VP16 was strongly inhibited (Fig. 4 b, lanes 4 and 5) , and this inhibition is likely to be due to destabilization of the binding of RBP-VP16 to DNA (Waltzer et al., 1996) . In the same assay, Gal4-EBNA3A(1-944) repressed RBP-VP16 transcriptional activation to the same extent as EBNA3A (Fig. 4 b, compare lanes 6 and 7 to lanes 4 and 5). As expected, Gal4-EBNA3A(125-234) prevented RBP-VP16 activation (Fig. 4 b,  lanes 8 and 9) , whereas Gal4-EBNA3A∆125-138 did not affect RBP-VP16-activated transcription (Fig. 4 b, lanes 10 and  11) . Taken together, our results strongly suggest that recruitment of RBP-Jκ is not required for Gal4-EBNA3A-mediated repression of transcription. The domain of EBNA3A mediating repression of transcription by Gal4-EBNA3A is located between amino acids 524 and 666
In order to identify precisely which region of EBNA3A was responsible for the transcriptional repression function of Gal4-EBNA3A, we analysed the repression activity of the Gal4-EBNA3A mutants shown in Fig. 5 (a) . These constructs were co-transfected in DG75 cells together with the reporter plasmid pG4-TK-CAT. The expression level of each fusion protein was evaluated by Western blot analysis, using a monoclonal antibody directed against the Gal4 DNA-binding domain. As shown in Fig. 5 (c) , all the proteins were expressed at comparable levels. The activity of the fusion proteins as repressor was then evaluated by measuring the amount of CAT protein expressed from the pG4-TK-CAT reporter. Again, Gal4-EBNA3A strongly repressed expression of the CAT protein (Fig. 5 b, compare lanes 3 and 4 to lane 1) and in a manner proportional to the amount (0n5 or 1 µg) of expression vector transfected. Deletion of the first 233 Nterminal amino acids of the protein had no effect on the repression capacity of the fusion protein (Fig. 5 b, lanes 5 and 6). Moreover, a fragment encompassing only amino acids 524-666 was still able to repress CAT expression to the same extent as the full-length protein (Fig. 5 b, compare lanes 11 and 12 to 3 and 4). Analysis of other overlapping mutants confirmed the localization of the repression domain since fusion proteins Gal4-EBNA3A(234-575) and , which contain only part of the domain delimited above, had respectively strongly reduced or no capacity to repress expression from pG4-TK-CAT (Fig. 5 b, lanes 7-8 and 9-10 respectively). Duplicate experiments performed in HeLa cells gave identical results (data not shown). Thus, we could conclude that the repression domain of EBNA3A lies between amino acids 524-666.
Discussion
In this report we provide experimental data demonstrating that EBNA3A tethered to DNA through the Gal4 DNAbinding domain represses transcription from a reporter gene carrying Gal4-DNA binding sites. We have identified a 143 amino acid domain of EBNA3A as being responsible for this repression. We have also precisely mapped the domain of EBNA3A involved in the interaction with the cellular factor RBP-Jκ.
An obvious explanation for the repressing properties of EBNA3A is that it can use endogenous RBP-Jκ as a co-factor for repression, since RBP-Jκ has been reported to be a repressor in mammalian cells. Our results strongly suggest that the EBNA3A repression domain is distinct from the interaction domain with RBP-Jκ. Furthermore, our results also suggest that, although EBNA3A most probably interacts with endogenous RBP-Jκ, the repression domain of RBP-Jκ is inactive when RBP-Jκ is complexed to EBNA3A. Indeed, EBNA3A mutants which did not interact with RBP-Jκ repressed reporter gene expression to the same level as the fusion containing fulllength EBNA3A, suggesting that there is no participation of RBP-Jκ in the observed repression. This inactivity of the RBP-Jκ repression domain, when bound to EBNA3A, is not so surprising because the smallest region of RBP-Jκ found to be necessary for RBP-Jκ-induced repression as well as for interaction with EBNA2 (Hsieh & Hayward, 1995) partially overlaps with the RBP-Jκ domain involved in EBNA3A and EBNA3C interaction (Krauer et al., 1996 ; Zhao et al., 1996 ; our report) . It is thus probable that the interactions of RBP-Jκ with the different cellular and viral partners described so far are mutually exclusive.
EBNA3s-RBP-Jκ interaction domains had previously been mapped to the N-terminal part of EBNA3A, 3B and 3C by using in vitro GST-RBPJκ pull-down assays of C-terminally truncated EBNA3 mutants (Robertson et al., 1996) . Here, we have delimited a more restricted 110 amino acid domain of EBNA3A (amino acids 125-234) which is necessary for the interaction with RBP-Jκ in vivo. This region is well-conserved between EBNA3A, EBNA3B and EBNA3C. In agreement with our results with EBNA3A, the RBP-Jκ interaction domain in EBNA3C has been mapped by Zhao et al. (1996) to the same conserved region.
Because of the conserved organization of the EBNA3 genes, it has been postulated that they have been generated by triplication of a common ancestral gene. Interaction with the cellular factor RBP-Jκ appears to be a well-conserved function of the EBNA3 proteins. We have shown here that another function of EBNA3A could be to repress gene expression. Similarly, EBNA3C has also been shown to be a repressor when fused to the Gal4 DNA-binding domain Waltzer et al., 1996) . However, in the case of EBNA3A we have mapped a unique 143 amino acid domain which is able to repress as efficiently as full-length EBNA3A when fused to the Gal4 DNA-binding domain. In contrast, for EBNA3C, two separate domains have been mapped which have additive repression activity . Nothing is known about the mechanisms by which Gal4-EBNA3A represses transcription. We have tried to evaluate if a co-factor was necessary for EBNA3A-induced repression. We therefore used the reporter construct pG4-TK-CAT and co-expressed increasing amounts of EBNA3A together with Gal4-EBNA3A in order to titrate a potential co-factor. No difference in the amount of CAT expressed from the pG4-TK-CAT reporter was detected, suggesting that if there is a co-factor it is not present in limited amounts in the cell nucleus (data not shown).
Thus, both EBNA3A and EBNA3C, and possibly EBNA3B, possess characteristics typical of transcriptional regulators. However, it is not yet known if and how they can be targeted to specific promoters. It has been reported that the EBNA3 proteins show some affinity for DNA when crude extracts from EBV-transformed cells are passed over DNA-cellulose columns (Kallin et al., 1986) , but no direct binding to DNA has DGI ever been described. The only cellular DNA-binding protein known at present to interact with EBNA3A, 3B and 3C is RBP-Jκ, and in this case the only effect of the interaction observed until now is disruption of the binding of RBP-Jκ to DNA. However, we cannot exclude the possibility that on certain promoters, EBNA3-RBP-Jκ complexes are stabilized by cellular co-factors, possibly binding onto the same promoter. The EBNA3 proteins could also be recruited onto the DNA by uncharacterized cellular DNA-binding factors acting as intermediary.
Moreover, other functions have been proposed for EBNA3C. In effect, EBNA3C can cooperate with activated (Ha-)ras, in co-transfection assays, to immortalize and transform rat embryo fibroblasts (Parker et al., 1996) . There is evidence that EBNA3C can act via the pRb-mediated pathway and as EBNA3C is able to directly bind a GST-pRb fusion in vitro (Parker et al., 1996) , it would be interesting to investigate whether EBNA3A is also able to interact with pRb and cooperate with (Ha-)ras to immortalize rat fibroblasts.
In conclusion, the EBNA3 proteins and especially EBNA3A and EBNA3C play an essential role in the immortalization of Blymphocytes by EBV, but their precise function is far from being understood. One possibility is that they could exert a retro-control on RBP-Jκ-EBNA2-activated genes. This retroregulation could be important as overexpression of a protein such as LMP1, for example, appears to be toxic for the cell Martin et al., 1993) . However, the role of the EBNA3 proteins can be expected to be more complex than this. Our work and that of others prompts us to regard the EBNA3 proteins as transcriptional regulators. The identification and characterization of potential cellular partners for these proteins is required for a better understanding of their precise role in EBV immortalization.
